Laura Pisarsky

Laura Pisarsky

Auto-generated profile, based on publicly available information

Laura Pisarsky

Boehringer Ingelheim RCV GmbH & Co KG, Vienna 1121, Austria

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Cancer Research
Verified
Journal Article
Closed access
AFAnna Fantozzi
Anna Fantozzi
DGDorothea C. Gruber
Dorothea C. Gruber
LPLaura Pisarsky
Laura Pisarsky
CHChantal Heck
Chantal Heck
AKAkiko Kunita
Akiko Kunita
GCGerhard Christofori
Gerhard Christofori
An epithelial–mesenchymal transition (EMT) underlies malignant tumor progression and metastatic spread by enabling cancer cells to depart from the primary tumor, invade surrounding tissue, and disseminate to distant organs. EMT also enriches for cancer stem cells (CSC) and increases the capacity of cancer cells to initiate and propagate tumors upon transplantation into immune-deficient mice, a major hallmark of CSCs. However, the molecular mechanisms promoting the tumorigenicity of cancer cells undergoing an EMT and of CSCs have remained widely elusive. We here report that EMT confers efficient tumorigenicity to murine breast cancer cells by the upregulated expression of the proangiogenic factor VEGF-A and by increased tumor angiogenesis. On the basis of these data, we propose a novel interpretation of the features of CSCs with EMT-induced, VEGF-A–mediated angiogenesis as the connecting mechanism between cancer cell stemness and tumor initiation. Cancer Res; 74(5); 1566–75. ©2014 AACR.

1 May 2016 in Cell Reports
Verified
Journal Article
Open access
LPLaura Pisarsky
Laura Pisarsky
RBRuben Bill
Ruben Bill
EFErnesta Fagiani
Ernesta Fagiani
SDSarah Dimeloe
Sarah Dimeloe
RGRyan William Goosen
Ryan William Goosen
GCGerhard Christofori
Gerhard Christofori
Despite the approval of several anti-angiogenic therapies, clinical results remain unsatisfactory, and transient benefits are followed by rapid tumor recurrence. Here, we demonstrate potent anti-angiogenic efficacy of the multi-kinase inhibitors nintedanib and sunitinib in a mouse model of breast cancer. However, after an initial regression, tumors resume growth in the absence of active tumor angiogenesis. Gene expression profiling of tumor cells reveals metabolic reprogramming toward anaerobic glycolysis. Indeed, combinatorial treatment with a glycolysis inhibitor (3PO) efficiently inhibits tumor growth. Moreover, tumors establish metabolic symbiosis, illustrated by the differential expression of MCT1 and MCT4, monocarboxylate transporters active in lactate exchange in glycolytic tumors. Accordingly, genetic ablation of MCT4 expression overcomes adaptive resistance against anti-angiogenic therapy. Hence, targeting metabolic symbiosis may be an attractive avenue to avoid resistance development to anti-angiogenic therapy in patients.

15 June 2018 in Biology of the Cell
Verified
Journal Article
Closed access
PDF file
EMElmina Mammadova‐Bach
Elmina Mammadova‐Bach
Tristan RuppTristan Rupp
Tristan Rupp
CSCaroline Spenlé
Caroline Spenlé
IJIvo Jivkov
Ivo Jivkov
PSPattabhiraman Shankaranarayanan
Pattabhiraman Shankaranarayanan
OLOlivier Lefebvre
Olivier Lefebvre
1

3 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
KMKathleen M. McAndrews
Kathleen M. McAndrews
FPFrancesca Paradiso
Francesca Paradiso
CSClint A. Stalnecker
Clint A. Stalnecker
BSBenson Chellakkan Selvanesan
Benson Chellakkan Selvanesan
FTFredrik I. Thege
Fredrik I. Thege
AMAnirban Maitra
Anirban Maitra
KRAS is among the most frequently mutated oncogenes in cancer, and for decades, efforts at pharmacological blockade of its function in solid cancers have been unsuccessful. A notable advance in this endeavor is the recent development of small-molecule KRAS inhibitors, which enable direct targeting of the mutant oncoprotein. Here, we comprehensively evaluated the preclinical efficacy of BI-2493, a first-in-class allele-agnostic mutant-KRAS inhibitor (panKRASi), in pancreatic ductal adenocarcinoma (PDAC). We report effective tumor growth suppression across a broad range of models, including cell lines, patient-derived xenografts (PDXs), and syngeneic orthotopic models, and prolonged survival in genetically engineered mouse models. Overall, transcriptomic, proteomic, and phosphoproteomic profiling of panKRASi-treated models confirmed RAS pathway inhibition along with up-regulation of LKB1/AMPK (liver kinase B1/AMP-activated protein kinase) targets. In panKRASi-treated immune-replete models, we observed increased intratumoral CD8 + effector T cells and decreased infiltration of myeloid cells, along with remodeling of the tumor microenvironment (TME), enabling responses to immune checkpoint blockade. In the long term, emergence of resistance to panKRASi monotherapy was associated with increased YAP signaling within tumor cells and enhanced expression of immune checkpoints in the TME that impede effective T cell function. Our multifaceted approach identified potential combinatorial approaches for generating sustained responses to panKRASi.

29 May 2015 in Angiogenesis
Verified
Journal Article
Closed access
PDF file
EFErnesta Fagiani
Ernesta Fagiani
RBRuben Bill
Ruben Bill
LPLaura Pisarsky
Laura Pisarsky
RIRobert Ivanek
Robert Ivanek
CRCurzio Rüegg
Curzio Rüegg
GCGerhard Christofori
Gerhard Christofori

17 June 2012 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
AZAdrian Zumsteg
Adrian Zumsteg
CCChristoph Caviezel
Christoph Caviezel
LPLaura Pisarsky
Laura Pisarsky
KSKarin Strittmatter
Karin Strittmatter
CGCarlos García-Echeverría
Carlos García-Echeverría
GCGerhard Christofori
Gerhard Christofori
NVP-AEW541, a specific ATP-competitive inhibitor of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase, has been reported to interfere with tumor growth in various tumor transplantation models. We have assessed the efficacy of NVP-AEW541 in repressing tumor growth and tumor progression in the Rip1Tag2 transgenic mouse model of pancreatic β-cell carcinogenesis. In addition, we have tested NVP-AEW541 in Rip1Tag2;RipIGF1R double-transgenic mice which show accelerated tumor growth and increased tumor malignancy compared with Rip1Tag2 single-transgenic mice. Previously, we have shown that high levels of IGF-2, a high-affinity ligand for IGF1R, are required for Rip1Tag2 tumor cell survival and tumor growth. Unexpectedly, treatment of Rip1Tag2 mice with NVP-AEW541 in prevention and intervention trials neither did affect tumor growth nor tumor cell proliferation and apoptosis. Yet, it significantly repressed progression to tumor malignancy, that is, the rate of the transition from differentiated adenoma to invasive carcinoma. Treatment of Rip1Tag2;RipIGF1R double-transgenic mice resulted in moderately reduced tumor volumes and increased rates of tumor cell apoptosis. Sustained expression of IGF-2 and of the IGF-2–binding form of insulin receptor (IR-A) in tumor cells suggests a compensatory role of IR-A upon IGF1R blockade. The results indicate that inhibition of IGF1R alone is not sufficient to efficiently block insulinoma growth and imply an overlapping role of IGF1R and insulin receptor in executing mitogenic and survival stimuli elicited by IGF-2. The reduction of tumor invasion upon IGF1R blockade on the other hand indicates a critical function of IGF1R signaling for the acquisition of a malignant phenotype. Mol Cancer Res; 10(6); 800–9. ©2012 AACR.